Player FM - Internet Radio Done Right
20 subscribers
Checked 9d ago
اضافه شده در four سال پیش
محتوای ارائه شده توسط Mayo Clinic Laboratories. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Mayo Clinic Laboratories یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !
با برنامه Player FM !
پادکست هایی که ارزش شنیدن دارند
حمایت شده
I think you could probably go back and track the stages of grief, probably that is what I went through. But I think if you do it right, you end up at acceptance. And that's where I ended up. And that's not to say that I've fully accepted the idea that the golden toad is extinct. Personally, I do still hold out hope that it could still be out there in those forests." - Trevor Ritland This conversation is with Trevor Ritland, who—along with his twin brother Kyle—authored The Golden Toad . The book chronicles their remarkable journey into Costa Rica’s cloud forest, once home to hundreds of brilliant golden toads that would emerge for just a few weeks each year—until, one day, they vanished without a trace. What began as a search for a lost species soon became something much more profound: a confrontation with ecological grief, a meditation on hope, and a powerful call to protect the natural world while we still can. Links: SpeciesUnite.com Kyle and Trevor: https://kyleandtrevor.com/ Instagram: https://www.instagram.com/adventureterm/ Goodreads - https://www.goodreads.com/book/show/222249677-the-golden-toad Amazon - https://www.amazon.com/Golden-Toad-Ecological-Mystery-Species/dp/163576996…
Answers from the Lab
علامت گذاری همه پخش شده(نشده) ...
Manage series 2908385
محتوای ارائه شده توسط Mayo Clinic Laboratories. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Mayo Clinic Laboratories یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.
…
continue reading
360 قسمت
علامت گذاری همه پخش شده(نشده) ...
Manage series 2908385
محتوای ارائه شده توسط Mayo Clinic Laboratories. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Mayo Clinic Laboratories یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.
…
continue reading
360 قسمت
همه قسمت ها
×In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, discuss summertime illnesses and key insights from a recent diagnostic investment event. Together, they explore: Common summertime illnesses, along with tips for prevention. How investment in diagnostic tools influences innovation in the laboratory. The potential impact of growing interest in AI investments. The investment interest in liquid biopsy and its potential implications for clinical decision-making. How AI development may accelerate adoption of mass spectrometry, proteomics, and similar advancements in clinical laboratories.…

1 Expanded assay better identifies hereditary pancreatitis: Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC 11:16
Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer. Speaker 4: (00:32) Could you both please tell us a little bit about yourself and your background? Speaker 4: (02:23) Could you please give the audience a brief overview of this assay? Speaker 4: (03:53) Which patients should have this test, and when should it be performed? Speaker 4: (04:49) What alternative testing options are available, and how do these compare to the new, expanded panel that we're going to be offering? Speaker 4: (08:20) How are the results used in patient care?…

1 How the Evolving Role of Diagnostics and Platforms Impact Healthcare: Bill Morice, M.D., Ph.D. 14:23
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed . They explore: The significant interest in diagnostics for the advancement of cancer care. The Joint Commission’s collaboration with the Coalition for Health AI to establish guidelines for the responsible use of artificial intelligence. The growing understanding that platforms offer an opportunity to expand access and make knowledge more accessible as platform-driven solutions become a reality. The role of laboratorians in guiding the ethical and effective use of data and emerging technologies — and what this means for educating future healthcare professionals. The critical importance of values and ethics in deploying new tools.…
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay ( Mayo ID: LBCS ) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound. (00:32) Can you tell us a little bit about yourself and your background? (01:33) Could you give us a brief overview of this assay? (02:47) Which patients should have this testing, and when should it be performed? (03:48) How would the results be used in patient care?…
John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed. Speaker 3: (00:33) Could you tell us a little about yourselves and your backgrounds? Speaker 3: (01:41) Dr. Taler, could you provide us with a brief background on resistant hypertension? Speaker 3: (03:43) Can you provide a little bit more background on patients who aren't taking their medications? Speaker 3: (05:11) How do physicians currently assess whether patients are taking their medications? Speaker 3: (07:03) Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension? Speaker 3: (09:43) Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S. , a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy. Their discussion covers: The high prevalence of peripheral neuropathy and why early diagnosis is important. The complexities involved in diagnosing the condition. Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process. How algorithms are enhancing the use of testing to complement other diagnostic tools. Ongoing discovery related to specific antibodies associated with neuropathies. Learn more in our e-book, " Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach ."…
Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay ( Mayo ID: ADVQU ) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children. (01:14) Could you give us a brief overview of this assay? (02:06) Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method? (04:00) When is this test typically ordered for transplant patients? Is it used throughout their treatment? (06:56) Could an immunocompromised person be unknowingly infected? (07:31) Is our quantitative method approved for pediatric patients? (08:00) How are the test results used to treat patients? (10:36) What other infections might providers consider alongside adeovirus?…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, discuss global trends in diagnostic manufacturing and their implications for laboratory professionals. Topics include: Emerging innovations in mass spectrometry, next-generation sequencing, automation, and artificial intelligence. Fierce competition in the global manufacturing landscape as new companies enter the market. Geopolitical dynamics influencing where innovations are deployed. Why laboratory professionals need to drive innovation implementation to maximize benefits for clinicians and their patients.…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the value laboratories deliver for their entire health system. They cover how laboratories impact: Growth in revenue Growth in lab charges Growth in ancillary services Hospital length of stay Control over expenses You can also find more in-depth information on this topic in “ Maximizing your health system’s financial performance ,” a white paper with data-driven ways laboratories support their organizations.…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss tick-borne diseases. They cover: Different diseases patients can get from ticks. Disease prevention, including Dr. Pritt’s A through Z flash cards with tips for people to protect themselves from infectious insects. Laboratory medicine’s valuable role in testing and educating providers to diagnose patients quickly and accurately. Clinical areas most likely to encounter patients with tick-borne diseases. Reliable sources for details about the prevalence of different diseases around the country (e.g., U.S. Centers for Disease Control and Prevention (CDC) and Mayo Clinic Laboratories ).…

1 Revolutionary Technology Advances Diagnosis of Neurodegenerative Disorders: Bill Morice, M.D., Ph.D. 22:09
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion . They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered: Details about how the cerebrospinal fluid biomarker test ( Mayo ID: ASYNC ) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes. Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians. Information physicians receive from the test, and when they should consider ordering it for their patients. Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN.…
Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk. (00:33) Do you mind telling us a little bit about yourself and your background? (01:45) Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation? (05:25) Which patients should have this testing, and when should it be performed? (06:57) What alternative test options are available, and how does testing at Mayo Clinic compare? (08:37) How are the results used in patient care?…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT). They covered: Details about the ruling to vacate the FDA’s rule on LDT oversight. What LDT oversight might look like in the future. How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation.…

1 Comprehensive Genetic Test Guides Prescribing of a Transplant Anti-Rejection Drug: Jessica Wright, Pharm.D., BCACP 15:20
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ. (00:32) Could you provide us a with little bit about your background and yourself? (03:45) Will you please provide a brief overview of Mayo test 3A5Q? (06:56) Which patients should have this testing, and when should it be performed? (08:15) What alternative or complementary tests should be considered? (09:25) How are the results used in patient care? (10:38) Will you help the audience understand the significance of monitoring tacrolimus levels for transplant rejection? (12:53) What alleles are included in this test?…
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence , to discuss liquid biopsy cancer testing . Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA. During their conversation, Dr. Morice and Dr. Tan explore: Inspiration for developing the liquid biopsy. Features that differentiate LiquidHALLMARK® from existing cancer tests. Patients who will benefit from the test and how an oncologist might use the results. The future potential of liquid biopsy advancements.…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the evolution of retail health. They cover several key topics, including: The emergence of retail health locations. Three types of care that are well-suited for a retail approach to healthcare. The importance of incorporating diagnostics when designing retail health. Keep up with the latest diagnostic news and Dr. Morice's insights on LinkedIn and X .…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss infectious disease activity around the nation. They cover: The high prevalence of influenza A, avian influenza, measles, and COVID-19. Reliable resources for information on the spread of infectious diseases. Prevention measures and their impact on the spread of infectious diseases. The risks associated with multiple infectious diseases circulating simultaneously at high rates.…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D. , director of the Infectious Diseases Serology Laboratory at Mayo Clinic, for a conversation about innovation in testing for sexually transmitted infections (STI). Topics include: The advantages and challenges of new types of specimen collection and testing methods, including over-the-counter, at-home, and point-of-care options. Implications home testing has for clinicians and public health. Barriers to making more at-home collection and over-the-counter testing products for STI testing. The growing need for tests to detect resistance markers as antimicrobial resistance increases.…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, for a conversation about quality management. Specifically, they discuss: The benefit of investing in quality management for patients, staff, and the organization. How Mayo Clinic’s Department of Laboratory Medicine and Pathology in Rochester evolved and grew its quality management program. The advantage of holding 5–10-minute huddles each day. How the lab leverages education on quality tools and Gemba Walks to empower all staff to invest in quality management.…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories. They discuss recent business trends in diagnostics and why it is important for pathologists to stay informed about these trends. Their conversation covers: What’s driving a renewed interest in investing in diagnostics. Why the knowledge pathologists have is so valuable in the current landscape. How the evolving expectations of laboratory professionals will make it important to stay informed about business trends.…
A
Answers from the Lab

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease. (00:32) Would you mind telling us a little bit about yourself and your background? (01:58) Would you give us an overview of membranous nephropathy? (07:14) Could you tell us a little bit about this new assay? (14:29) Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories. They discuss Dr. Morice’s recent article in Becker’s Hospital Review, “ Nine Developments Predicted to Shape Laboratory Medicine and Diagnostics in 2025 ,” and go deeper into conversation about: The rapid evolution of artificial intelligence and large language models. Digital pathology. Proteomics, metabolomics, and mass spectrometry.…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Erin Graf, Ph.D., co-director of Microbiology in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Arizona, to discuss benefits of automation in the laboratory. Topics of discussion include: Specific examples of how they are using automation in the laboratory. Strategies for ensuring a smooth implementation and a positive experience for staff. The potential of automation to support staff and continued patient care excellence amid projected labor shortages in the future.…
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss emerging concerns about H5N1 avian influenza. Specific topics of discussion include: Patterns of transmission and what they indicate about the potential of person-to-person transmission. Tools, tests, and processes that emerged in recent years that are making it easier to understand and track this virus. Remaining unknowns about the virus and how it could evolve.…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the progress of artificial intelligence (AI) and what’s next in this space. Specific topics of discussion include: What’s driving the rapid acceleration of AI advancements. Ethical concerns and opportunities. How expenses, payment models, and culture influence AI advancements. The need to rethink training and education amid the rise of AI solutions.…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss the latest in infectious disease outbreaks. Specific topics of discussion include: Recent trends in the spread of H5 bird flu and dengue fever. Why it’s important to think globally when monitoring infectious diseases. Extra precautions to take during the holiday travel season to keep you and those around you healthy.…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss how labs can enhance patient access to improve health equity. Specific topics of discussion include: Innovations creating new possibilities, such as mobile clinics, at-home tests, and artificial intelligence. The responsibility of laboratory professionals to help guide the use of these new tools and the importance of collaboration between health systems. What’s needed to make solutions scalable and sustainable. Learn more in Dr. Morice’s “Lab Manager” article .…
A
Answers from the Lab

1 Making Informed Decisions About Genetic Testing: Carrie Lahner, M.S., CGC, and April Studinski Jones, M.S., CGC 18:50
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by genetic counselors Carrie Lahner, M.S., CGC, and April Studinski Jones, M.S., CGC, to discuss how family medical history can inform genetic testing strategies. Specific topics of discussion include: The seven main types of genetic testing, and how clinicians know when and what genetic testing to order. Key family history details to collect to inform decisions about genetic testing. How genetic counselors collaborate with physicians and laboratorians to make testing decisions. Recent genetic testing advancements that are improving diagnostics.…
A
Answers from the Lab

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent. (00:32) Could you give us a brief overview about your background and yourself? (02:16) Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan? (05:34) What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories? (08:01) Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate? (10:36) Could you elaborate on the specific clinical indications for testing in relation to irinotecan? (13:27) How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results? (14:02) Are there any other factors or related genes that should be considered alongside UGT1A1 , particularly for cancer therapy?…
A
Answers from the Lab

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , CEO and president of Mayo Clinic Laboratories, to discuss recent outbreaks in vaccine-preventable diseases. Specific topics of discussion include: Recent increases in outbreaks of infectious diseases, such as pertussis, measles , and polio. The serious side effects of the diseases. What’s fueling the resurgence of these diseases. Testing options for infectious diseases and resources for physicians.…
به Player FM خوش آمدید!
Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.